

**Demographic and Clinical Characteristics of Patients With First-Episode Schizophrenia Spectrum Disorders Randomly Assigned to Treatment With Olanzapine or Risperidone<sup>a</sup>**

Characteristic	All Subjects (N=112)		Olanzapine-Treated Subjects (N=56)		Risperidone-Treated Subjects (N=56)	
	N	%	N	%	N	%
Men	78	70	40	71	38	68
Women	34	30	16	29	18	32
Ethnic background						
African-American	60	54	31	55	29	52
Caucasian	22	20	12	22	10	18
Hispanic	15	13	4	7	11	20
Asian	7	6	3	5	4	7
Other/mixed	8	7	6	11	2	3
Marital status						
Never married	100	89	49	88	51	91
Married	5	5	4	7	1	2
Divorced	6	5	3	5	3	5
Unknown	1	1	0		1	2
Diagnosis						
Schizophrenia	84	75	44	79	40	71
Schizophreniform disorder	19	17	9	16	10	18
Schizoaffective disorder	9	8	3	5	6	11
	Mean	SD	Mean	SD	Mean	SD
Age (years)	23.3	5.1	23.3	4.5	23.4	5.5
Highest educational level (1=postgraduate; 7=grade school)	3.9	1.1	3.9	0.9	4.0	1.2
Hollingshead social class						
Subject	4.2	0.9	4.2	0.9	4.3	0.9
Parent	3.2	1.2	3.2	1.1	3.2	1.3
Age at first psychiatric symptoms (years)	18.8	5.9	19.6	5.9	18.1	5.7
Age at first psychotic symptoms (years)	20.7	5.7	21.6	5.4	20.5	4.7
Duration of psychiatric symptoms before study entry (weeks)	225.9	255.0	193.6	219.3	247.6	280.4
Duration of psychotic symptoms before study entry (weeks)	113.1	158.8	89.7	107.8	136.2	194.0
Severity of delusions at study entry	5.3	0.8	5.4	0.7	5.2	0.9
Severity of hallucinations at study entry	4.6	1.5	4.5	1.5	4.7	1.4
GAS score at study entry	24.3	6.9	23.9	7.0	24.8	6.9
Severity of negative symptoms at study entry						
Affective flattening	2.0	1.0	2.0	1.1	2.0	1.0
Alogia	1.9	1.0	1.9	1.0	1.9	1.1
Avolition-apathy	2.9	1.3	2.8	1.3	3.0	1.3

Asociality-anhedonia	3.1	1.1	3.1	1.2	3.2	1.1
----------------------	-----	-----	-----	-----	-----	-----

<sup>a</sup>There were no differences between olanzapine and risperidone groups on any characteristic.